BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 18810795)

  • 1. Contaminated heparin.
    Kakkar AK; Bonnefoi M
    N Engl J Med; 2008 Sep; 359(12):1292-3; author reply 1293. PubMed ID: 18810795
    [No Abstract]   [Full Text] [Related]  

  • 2. [Artificial polysaccharide in contaminated heparin. Acute hypersensitivity reactions explained--but how could it happen?].
    Lindahl U
    Lakartidningen; 2008 Sep 24-30; 105(39):2660-1. PubMed ID: 18846871
    [No Abstract]   [Full Text] [Related]  

  • 3. Contaminated heparin.
    Greinacher A; Warkentin TE
    N Engl J Med; 2008 Sep; 359(12):1291-2; author reply 1293. PubMed ID: 18799565
    [No Abstract]   [Full Text] [Related]  

  • 4. Contaminated heparin associated with adverse clinical events and activation of the contact system.
    Kishimoto TK; Viswanathan K; Ganguly T; Elankumaran S; Smith S; Pelzer K; Lansing JC; Sriranganathan N; Zhao G; Galcheva-Gargova Z; Al-Hakim A; Bailey GS; Fraser B; Roy S; Rogers-Cotrone T; Buhse L; Whary M; Fox J; Nasr M; Dal Pan GJ; Shriver Z; Langer RS; Venkataraman G; Austen KF; Woodcock J; Sasisekharan R
    N Engl J Med; 2008 Jun; 358(23):2457-67. PubMed ID: 18434646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin comes clean.
    Schwartz LB
    N Engl J Med; 2008 Jun; 358(23):2505-9. PubMed ID: 18525048
    [No Abstract]   [Full Text] [Related]  

  • 6. Oversulfated chondroitin sulfate and OSCS-contaminated heparin cause dose- and route-dependent hemodynamic effects in the rat.
    Corbier A; Le Berre N; Rampe D; Meng H; Lorenz M; Vicat P; Potdevin S; Doubovetzky M
    Toxicol Sci; 2011 Jun; 121(2):417-27. PubMed ID: 21436127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The tainted heparin story: an update.
    Guerrini M; Shriver Z; Bisio A; Naggi A; Casu B; Sasisekharan R; Torri G
    Thromb Haemost; 2009 Nov; 102(5):907-11. PubMed ID: 19888527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contaminants in heparins continue to be unfolded.
    Fareed J; Ahluwalia M; Wahi R; Ramaccioti E; Hoppensteadt D; Bick RL
    Int Angiol; 2008 Dec; 27(6):457-61. PubMed ID: 19078906
    [No Abstract]   [Full Text] [Related]  

  • 9. Structure elucidation and biological activity of the oversulfated chondroitin sulfate contaminant in Baxter heparin.
    McKee J; Bairstow S; Szabo C; Ray J; Wielgos T; Hu P; Chess E; Nordhaus M; Hai T; Campbell J; Donovan S; Viseux N; Riedel N; Cammack J; Johnson R
    J Clin Pharmacol; 2010 Oct; 50(10):1159-70. PubMed ID: 20147614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contaminants in heparins: are all facts known?
    Fareed J; Hoppensteadt DA; Ramacciotti E; Hull RD
    Clin Appl Thromb Hemost; 2010 Jun; 16(3):242-3. PubMed ID: 20547552
    [No Abstract]   [Full Text] [Related]  

  • 11. Contaminated heparin-affected patient plasmas are associated with activated contact systems.
    Yi Qian ; Jing Pan ; Xiaodong Zhou ; Weiser P; Hong Lu ; Beck AM; Shih FF; Lijuan Zhang
    Clin Appl Thromb Hemost; 2010 Jun; 16(3):261-5. PubMed ID: 20547554
    [No Abstract]   [Full Text] [Related]  

  • 12. Identification of a simple and sensitive microplate method for the detection of oversulfated chondroitin sulfate in heparin products.
    Bairstow S; McKee J; Nordhaus M; Johnson R
    Anal Biochem; 2009 May; 388(2):317-21. PubMed ID: 19289093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anaphylactoid reactions associated with contaminated heparin from China].
    Montpas N; Désormeaux A; Keire D; Adam A
    Ann Pharm Fr; 2011 Sep; 69(5):258-64. PubMed ID: 21924126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review: contaminants in heparin: review of the literature, molecular profiling, and clinical implications.
    Ramacciotti E; Clark M; Sadeghi N; Hoppensteadt D; Thethi I; Gomes M; Fareed J
    Clin Appl Thromb Hemost; 2011 Apr; 17(2):126-35. PubMed ID: 21288929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From crisis to opportunity: a perspective on the heparin crisis.
    Sasisekharan R; Shriver Z
    Thromb Haemost; 2009 Nov; 102(5):854-8. PubMed ID: 19888519
    [No Abstract]   [Full Text] [Related]  

  • 16. Contaminants in heparin.
    Hull R; Walenga J
    Clin Appl Thromb Hemost; 2011 Apr; 17(2):125. PubMed ID: 21406418
    [No Abstract]   [Full Text] [Related]  

  • 17. Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes.
    Warkentin TE; Greinacher A
    Expert Opin Drug Saf; 2009 Mar; 8(2):129-44. PubMed ID: 19309242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of cytokine secretion from lymphocytes of patients with hypersensitivity reactions to contaminated heparins.
    Martin M; Ott H; Merk HF; Sachs B
    Br J Dermatol; 2011 Jan; 164(1):68-75. PubMed ID: 20854434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contaminated heparin preparations, severe adverse events and the contact system.
    Ramacciotti E; Wahi R; Messmore HL
    Clin Appl Thromb Hemost; 2008 Oct; 14(4):489-91. PubMed ID: 18815138
    [No Abstract]   [Full Text] [Related]  

  • 20. Prothrombin time for detection of contaminated heparins.
    Alban S; Lühn S
    N Engl J Med; 2008 Dec; 359(25):2732-4. PubMed ID: 19052118
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.